In this edition:
Treatment patterns/outcomes of poor-prognosis AML in Australia & NZ
INTERCEPT: pre-emptive revumenib for MRD in NPM1-mutated or KMT2A-rearranged AML
DIAAMOND: avatrombopag + immunosuppressive therapy in treatment-naïve severe aplastic anaemia
DIAAMOND: cellular & cell-free molecular profiling
COALITION: glofitamab-R-CHOP or glofitamab-polatuzumab-R-CHP in younger, high-risk LBCL
Dysregulated complement activation in PV
AMPLIFY: fixed-duration acalabrutinib-venetoclax ± obinutuzumab in treatment-naïve CLL
Phase 1 CaDAnCe-101: a novel BTK degrader in relapsed/refractory Waldenström macroglobulinemia
EA4151: no benefit from autologous stem cell transplantat in MCL in first CR with undetectable MRD
LUNA 3: rilzabrutinib in primary persistent/chronic ITP
Stay up to date with our latest clinical information.
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.